-
21.发明申请PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF 审中-公开PROSTAGLANDIN和PROSTAMIDE药物输送系统及其内科治疗用途公开(公告)号：US20100104654A1
公开(公告)日：2010-04-29
申请号：US12259153
申请日：2008-10-27
Applicant: Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
Inventor： Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
IPC: A61K9/14 , A61K31/216
CPC classification number: A61L31/06 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/204 , A61K31/216 , A61K31/557 , A61K31/5575 , A61L31/16
Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
Abstract translation: 生物相容性，生物可侵蚀的植入物和微球体包括拉坦前列素和可生物降解的聚合物，当放置眼内（如进入subtenon空间）治疗青光眼时有效。
-
公开(公告)号：US20090196906A1
公开(公告)日：2009-08-06
申请号：US12319356
申请日：2009-01-05
Applicant: Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster
Inventor： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster
IPC: A61F2/14 , A61K31/44 , A61K31/444 , A61K31/4439 , A61K31/4436 , A61K31/5377 , A61K31/496 , A61K31/541 , A61K31/4545
CPC classification number: C07D213/82 , A61K9/0051 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K47/34 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D417/06 , Y02A50/401
Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
23.发明申请公开(公告)号：US20090196905A1
公开(公告)日：2009-08-06
申请号：US12026736
申请日：2008-02-06
Applicant: Lon T. Spada , Wendy M. Blanda , Marianne M. Do , Scott M. Whitcup , Patrick M. Hughes , Michael R. Robinson
Inventor： Lon T. Spada , Wendy M. Blanda , Marianne M. Do , Scott M. Whitcup , Patrick M. Hughes , Michael R. Robinson
CPC classification number: A61K38/13 , A61F9/0017 , A61F2210/0004
Abstract: Methods of treating ocular diseases and conditions using biodegradable ocular implants containing cyclosporine to inhibit mitochondrial permeability transition pore formation are disclosed.
Abstract translation: 公开了使用含有环孢菌素的生物降解性眼部植入物治疗眼部疾病和病症以抑制线粒体通透性转换孔形成的方法。
-
公开(公告)号：US08969415B2
公开(公告)日：2015-03-03
申请号：US11565917
申请日：2006-12-01
Applicant: Michael R. Robinson , Wendy M. Blanda , Patrick M. Hughes , Guadalupe Ruiz , Werhner C. Orilla , Scott M. Whitcup , Devin F. Welty , Joan-En Lin , Lon T. Spada
Inventor： Michael R. Robinson , Wendy M. Blanda , Patrick M. Hughes , Guadalupe Ruiz , Werhner C. Orilla , Scott M. Whitcup , Devin F. Welty , Joan-En Lin , Lon T. Spada
IPC: A61K31/165 , A61F2/00 , A61K31/565 , A61F9/00 , A61K9/00 , A61K9/16 , A61K9/50 , A61K31/498 , A61K31/557 , A61K9/10
CPC classification number: A61K31/565 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K9/10 , A61K9/1635 , A61K9/1694 , A61K9/5031 , A61K31/498 , A61K31/557 , A61K47/34 , Y10S514/913
Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
Abstract translation: 尺寸适于植入眼部或部位的可生物降解植入物以及用于治疗眼部病症的方法。 植入物以治疗有效量提供活性剂在10天至1年或更长时间内的延长释放。
-
公开(公告)号：US08946170B2
公开(公告)日：2015-02-03
申请号：US13187117
申请日：2011-07-20
Applicant: Hongwen M. Rivers , Lon T. Spada , Michelle Luu
Inventor： Hongwen M. Rivers , Lon T. Spada , Michelle Luu
IPC: A61K47/34 , A61K48/00 , A61K9/00 , A61K31/7088 , A61K31/713 , A61K47/48
CPC classification number: A61K9/0051 , A61K31/7088 , A61K31/713 , A61K47/34 , A61K47/543 , A61K47/64 , A61K47/6455 , A61K48/0075 , C12N15/113 , C12N2310/14 , C12N2310/3513 , C12N2310/3515
Abstract: An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.
Abstract translation: 描述了包含与选自阳离子脂质和短细胞穿透肽的转染剂复合的siRNA的眼部植入物，其中所述复合物与生物相容性聚合物缔合。 生物相容性聚合物包含配置成以治疗水平将复合物释放到患者眼中足以治疗眼部疾病或疾病的聚合物基质。
-
Patent Agency Ranking
26.发明授权Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof 有权前列腺素和前列腺酰胺药物递送系统及其眼内治疗用途公开(公告)号：US08771745B2
公开(公告)日：2014-07-08
申请号：US13596904
申请日：2012-08-28
Applicant: Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
Inventor： Michael R. Robinson , Hui Liu , Patrick M. Hughes , Lon T. Spada , Alazar N. Ghebremeskel
CPC classification number: A61L31/06 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/204 , A61K31/216 , A61K31/557 , A61K31/5575 , A61L31/16
Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
Abstract translation: 生物相容性，生物可侵蚀的植入物和微球体包括拉坦前列素和可生物降解的聚合物，当放置眼内（如进入subtenon空间）治疗青光眼时有效。
-
公开(公告)号：US08455656B2
公开(公告)日：2013-06-04
申请号：US12380493
申请日：2009-02-26
Applicant: Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
Inventor： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
IPC: A61K31/40 , A61F9/007 , C07D213/00
CPC classification number: C07D405/04 , A61K9/0051 , A61K9/5031 , A61K31/397 , A61K31/404 , A61K31/41 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/82 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06
Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
公开(公告)号：US08383825B2
公开(公告)日：2013-02-26
申请号：US13178277
申请日：2011-07-07
Applicant: Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
Inventor： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
IPC: C07D211/72 , A61K31/44 , A61K31/50
CPC classification number: C07D213/82 , A61K9/0051 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K47/34 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D417/06 , Y02A50/401
Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
公开(公告)号：US20110077229A1
公开(公告)日：2011-03-31
申请号：US12960971
申请日：2010-12-06
Applicant: Jeffrey L. Edelman , Kelly M. Harrison , Patrick M. Hughes , Lon T. Spada
Inventor： Jeffrey L. Edelman , Kelly M. Harrison , Patrick M. Hughes , Lon T. Spada
IPC: A61K31/573 , A61K31/56 , A61P27/02
CPC classification number: A61K31/573 , A61K9/0048 , A61K9/0051 , A61K9/06 , A61K31/56 , A61K47/36
Abstract: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.
Abstract translation: 公开了包含糖皮质激素衍生物的糖皮质激素衍生物的药物组合物，例如与生物可降解聚合物如聚（丙交酯 - 共 - 乙交酯）聚合物或高分子量聚合物透明质酸混合的17,21-二丙酸倍氯米松。
-
公开(公告)号：US07749530B2
公开(公告)日：2010-07-06
申请号：US12317469
申请日：2008-12-23
Applicant: Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Wendy M. Blanda
Inventor： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Wendy M. Blanda
IPC: A61K31/404
CPC classification number: A61K9/204 , A61K9/0051 , A61K31/404 , C07D209/34 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D495/04 , C07D513/04 , C40B40/04 , Y10S514/954
Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
Abstract translation: 本发明涉及药物递送系统，其包括眼部植入物，其包括能够调节酪氨酸激酶信号转导以调节，调节和/或抑制异常细胞增殖的有机分子，所述聚合物用于控制聚合物， 改变，调节和/或缓慢释放治疗组分到其中放置所述复合物的眼睛的环境中。
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.029 seconds)
